المؤلفون: Bhatt, Sucheta, Taylor, Annette K., Lozano, Reymundo, Grody, Wayne W., Griffin, John H.

المصدر: Genetics in Medicine ; volume 23, issue 12, page 2463 ; ISSN 1098-3600

مصطلحات موضوعية: Genetics (clinical)

الإتاحة: https://doi.org/10.1038/s41436-021-01108-xTest
https://www.nature.com/articles/s41436-021-01108-x.pdfTest
https://www.nature.com/articles/s41436-021-01108-xTest
https://api.elsevier.com/content/article/PII:S1098360021054563?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1098360021054563?httpAccept=text/plainTest

المؤلفون: Crowley, James J., Szatkiewicz, Jin, Kähler, Anna K., Giusti-Rodriguez, Paola, Ancalade, NaEshia, Booker, Jessica K., Carr, Jennifer L., Giamberardino, Stephanie N., Crawford, Greg E., Losh, Molly, Stockmeier, Craig A., Taylor, Annette K., Piven, Joseph, Sullivan, Patrick F.

المصدر: Molecular Psychiatry ; volume 25, issue 12, page 3450-3450 ; ISSN 1359-4184 1476-5578

مصطلحات موضوعية: Cellular and Molecular Neuroscience, Psychiatry and Mental health, Molecular Biology

الإتاحة: https://doi.org/10.1038/s41380-019-0526-xTest
https://www.nature.com/articles/s41380-019-0526-x.pdfTest
https://www.nature.com/articles/s41380-019-0526-xTest

المؤلفون: Zhang, Shulin, Taylor, Annette K., Huang, Xuan, Luo, Biao, Spector, Elaine B., Fang, Ping, Richards, C. Sue

المصدر: Genetics in Medicine ; volume 20, issue 12, page 1489-1498 ; ISSN 1098-3600

مصطلحات موضوعية: Genetics (clinical)

الإتاحة: https://doi.org/10.1038/s41436-018-0322-zTest
http://www.nature.com/articles/s41436-018-0322-zTest
http://www.nature.com/articles/s41436-018-0322-z.pdfTest
https://api.elsevier.com/content/article/PII:S1098360021000265?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1098360021000265?httpAccept=text/plainTest

المؤلفون: Bailey, Donald B., Hatton, Deborah D., Tassone, Flora, Skinner, Martie, Taylor, Annette K.

المصدر: American Journal on Mental Retardation. Jan 2001 106(1):16-27.

تمت مراجعته من قبل الزملاء: N

Page Count: 12

الواصفات: Biochemistry, Congenital Impairments, Etiology, Genetics, Males, Mental Retardation, Young Children

المؤلفون: Luzum, Jasmine A., Petry, Natasha, Taylor, Annette K., Van Driest, Sara L., Dunnenberger, Henry M., Cavallari, Larisa H.

مصطلحات موضوعية: Pharmacy and Pharmacology, Health Sciences

وصف الملف: application/pdf

العلاقة: Luzum, Jasmine A.; Petry, Natasha; Taylor, Annette K.; Van Driest, Sara L.; Dunnenberger, Henry M.; Cavallari, Larisa H. (2021). "Moving Pharmacogenetics Into Practice: It’s All About the Evidence!." Clinical Pharmacology & Therapeutics (3): 649-661.; https://hdl.handle.net/2027.42/169310Test; Clinical Pharmacology & Therapeutics; Clinical Pharmacogenetics Implementation Consortium. PGx Dissemination Working Group < https://cpicpgx.org/disseminationTest/ > ( 2021 ).; Mukherjee, C., Sweet, K.M., Luzum, J.A., Abdel‐Rasoul, M., Christman, M.F. & Kitzmiller, J.P. Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. Per. Med. 14, 383 – 388 ( 2017 ).; Thornley, T., Esquivel, B., Wright, D.J., Dop, H.V.D., Kirkdale, C.L. & Youssef, E. Implementation of a pharmacogenomic testing service through community pharmacy in the Netherlands: results from an early service evaluation. Pharmacy (Basel) 9, 38 ( 2021 ).; Bielinski, S.J. et al. Are patients willing to incur out‐of‐pocket costs for pharmacogenomic testing? Pharmacogenomics J. 17, 1 – 3 ( 2017 ).; Empey, P.E., Pratt, V.M., Hoffman, J.M., Caudle, K.E. & Klein, T.E. Expanding evidence leads to new pharmacogenomics payer coverage. Genet. Med. 23, 830 – 832 ( 2021 ).; Holzer, K. et al. Hmong participants’ reactions to return of individual and community pharmacogenetic research results: "A positive light for our community". J. Commun. Genet. 12, 53 – 65 ( 2021 ).; Lemke, A.A. et al. Patient perspectives following pharmacogenomics results disclosure in an integrated health system. Pharmacogenomics 19, 321 – 331 ( 2018 ).; Christian, C. et al. Pharmacogenomic‐based decision support to predict adherence to medications. Clin. Pharmacol. Ther. 108, 368 – 376 ( 2020 ).; Truong, T.M., Lipschultz, E., Schierer, E., Danahey, K., Ratain, M.J. & O’Donnell, P.H. Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet. Genomics 30, 191 – 200 ( 2020 ).; Drelles, K., Pilarski, R., Manickam, K., Shoben, A.B. & Toland, A.E. Impact of previous genetic counseling and objective numeracy on accurate interpretation of a pharmacogenetics test report. Public Health Genomics 24, 26 – 32 ( 2021 ).; Roden, D.M. et al. Benefit of preemptive pharmacogenetic information on clinical outcome. Clin. Pharmacol. Ther. 103, 787 – 794 ( 2018 ).; Weitzel, K.W., Cavallari, L.H. & Lesko, L.J. Preemptive panel‐based pharmacogenetic testing: the time is now. Pharm. Res. 34, 1551 – 1555 ( 2017 ).; Zhu, Y. et al. A model‐based cost‐effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet. Med. 23, 461 – 470 ( 2020 ).; Van Driest, S.L. et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin. Pharmacol. Ther. 95, 423 – 431 ( 2014 ).; Schildcrout, J.S. et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235 – 242 ( 2012 ).; Saldivar, J.‐S. et al. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long‐term care facility. Pharmgenomics Pers. Med. 9, 1 – 6 ( 2016 ).; Halverson, C.M., Pratt, V.M., Skaar, T.C. & Schwartz, P.H. Ending the pharmacogenomic gag rule: the imperative to report all results. Pharmacogenomics 22, 191 – 193 ( 2021 ).; Pratt, V.M. et al. Characterization of 137 genomic DNA reference materials for 28 pharmacogenetic genes: A GeT‐RM collaborative project. J. Mol. Diagn. 18, 109 – 123 ( 2016 ).; United States Food and Drug Administration. The FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications: FDA Safety Communication < https://www.fda.gov/medicalTest‐devices/safety‐communications/fda‐warns‐against‐use‐many‐genetic‐tests‐unapproved‐claims‐predict‐patient‐response‐specific#actions > ( 2018 ).; Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450 – 458 ( 2012 ).; Owusu Obeng, A. et al. Physician‐reported benefits and barriers to clinical implementation of genomic medicine: a multi‐site IGNITE‐Network Survey. J. Pers. Med. 8, 24 ( 2018 ).; Woodcock, J. Assessing the clinical utility of diagnostics used in drug therapy. Clin. Pharmacol. Ther. 88, 765 – 773 ( 2010 ).; Munar, M.Y. & Singh, H. Drug dosing adjustments in patients with chronic kidney disease. Am. Fam. Physician 75, 1487 – 1496 ( 2007 ).; Dunnenberger, H.M. et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol. 55, 89 – 106 ( 2015 ).; Hicks, J.K. et al. Implementation of clinical pharmacogenomics within a large health system: from electronic health record decision support to consultation services. Pharmacotherapy 36, 940 – 948 ( 2016 ).; Cavallari, L.H. et al. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real‐world setting. Clin. Transl. Sci. 10, 143 – 146 ( 2017 ).; van der Wouden, C.H. et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin. Pharmacol. Ther. 101, 341 – 358 ( 2017 ).; Petry, N. et al. Implementation of wide‐scale pharmacogenetic testing in primary care. Pharmacogenomics 20, 903 – 913 ( 2019 ).; Luzum, J.A. et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin. Pharmacol. Ther. 102, 502 – 510 ( 2017 ).; Nissen, S.E. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 306, 2727 – 2728 ( 2011 ).; van der Wouden, C.H., Swen, J.J., Samwald, M., Mitropoulou, C., Schwab, M. & Guchelaar, H.J. A brighter future for the implementation of pharmacogenomic testing. Eur. J. Hum. Genet. 24, 1658 – 1660 ( 2016 ).; Pirmohamed, M. & Hughes, D.A. Pharmacogenetic tests: the need for a level playing field. Nat. Rev. Drug Discovery 12, 3 – 4 ( 2013 ).; Khoury, M.J. Dealing with the evidence dilemma in genomics and personalized medicine. Clin. Pharmacol. Ther. 87, 635 – 638 ( 2010 ).; Frueh, F.W. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 10, 1077 – 1081 ( 2009 ).; Denny, J.C., Schildcrout, J.S., Pulley, J.M. & Roden, D.M. Response to "Doubt about the feasibility of preemptive genotyping". Clin. Pharmacol. Ther. 93, 234 ( 2013 ).; Huddart, R., Sangkuhl, K., Whirl‐Carrillo, M. & Klein, T.E. Are randomized controlled trials necessary to establish the value of implementing pharmacogenomics in the clinic? Clin. Pharmacol. Ther. 106, 284 – 286 ( 2019 ).; Bottorff, M.B., Bright, D.R. & Kisor, D.F. Commentary: should pharmacogenomic evidence be considered in clinical decision making? Focus on select cardiovascular drugs. Pharmacotherapy 37, 1005 – 1013 ( 2017 ).; Drozda, K. & Pacanowski, M.A. Clinical trial designs to support clinical utility of pharmacogenomic testing. Pharmacotherapy 37, 1000 – 1004 ( 2017 ).; Caudle, K.E., Gammal, R.S., Whirl‐Carrillo, M., Hoffman, J.M., Relling, M.V. & Klein, T.E. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am. J. Health Syst. Pharm. 73, 1977 – 1985 ( 2016 ).; Gillis, N.K. & Innocenti, F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin. Pharmacol. Ther. 96, 655 – 657 ( 2014 ).; Janssens, A.C. & Deverka, P.A. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin. Pharmacol. Ther. 96, 652 – 654 ( 2014 ).; Ratain, M.J. & Johnson, J.A. Meaningful use of pharmacogenetics. Clin. Pharmacol. Ther. 96, 650 – 652 ( 2014 ).; Altman, R.B. Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin. Pharmacol. Ther. 89, 348 – 350 ( 2011 ).; Evans, B.J. Establishing clinical utility of pharmacogenetic tests in the post‐FDAAA era. Clin. Pharmacol. Ther. 88, 749 – 751 ( 2010 ).; Woodcock, J. The human genome and translational research: how much evidence is enough? Health Affairs (Project Hope) 27, 1616 – 1618 ( 2008 ).; Zineh, I. & Lesko, L.J. Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. Per. Med. 6, 359 – 361 ( 2009 ).; Koch, B.C., van Schaik, R.H., van Gelder, T. & Mathijssen, R.H. & Rotterdam Clinical Pharmacology‐Pharmacogenetics Group (RCPPG). Doubt about the feasibility of preemptive genotyping. Clin. Pharmacol. Ther. 93, 233 ( 2013 ).; Wang, B., Canestaro, W.J. & Choudhry, N.K. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. JAMA Intern. Med. 174, 1938 – 1944 ( 2014 ).; Relling, M.V., Altman, R.B., Goetz, M.P. & Evans, W.E. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507 – 509 ( 2010 ).; Relling, M.V. & Evans, W.E. Pharmacogenomics in the clinic. Nature 526, 343 – 350 ( 2015 ).; Harris, L.N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early‐stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 34, 1134 – 1150 ( 2016 ).; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer < https://www2.triTest‐kobe.org/nccn/guideline/breast/english/breast.pdf > ( 2020 ).; Goetz, M.P. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin. Pharmacol. Ther. 103, 770 – 777 ( 2018 ).; Brauch, H., Schroth, W., Eichelbaum, M., Schwab, M. & Harbeck, N. Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer. Breast Care 3, 43 – 50 ( 2008 ).; Dean, L. Tamoxifen therapy and CYP2D6 genotype. In Medical Genetics Summaries (eds. Pratt, V.M., Scott, S.A., Pirmohamed, M., Esquivel, B., Kane, M.S. & Kattman, B.L. et al.) 501 – 516 ( National Center for Biotechnology Information, Bethesda, MD, 2019 ).; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient‐level meta‐analysis of the randomised trials. Lancet 386, 1341 – 1352 ( 2015 ).; United States Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling < https://www.fda.gov/drugs/scienceTest‐and‐research‐drugs/table‐pharmacogenomic‐biomarkers‐drug‐labeling > ( 2015 ).; United States Food and Drug Administration. Clopidogrel Prescribing Information < https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020839s074lbl.pdfTest > ( 2017 ).; United States Food and Drug Administration. Table of Pharmacogenetic Associations < https://www.fda.gov/medicalTest‐devices/precision‐medicine/table‐pharmacogenetic‐associations > ( 2020 ).; Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464 – 467 ( 2011 ).; Swen, J.J. et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin. Pharmacol. Ther. 89, 662 – 673 ( 2011 ).; Ross, C.J. et al. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid 20, 681 – 687 ( 2010 ).; Caudle, K.E. et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug. Metab. 15, 209 – 217 ( 2014 ).; Hewett, M. et al. PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res. 30, 163 – 165 ( 2002 ).; United States Food and Drug Administration. Prescribing Information for Tamoxifen < https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdfTest > ( 2018 ).; Caudle, K.E., Keeling, N.J., Klein, T.E., Whirl‐Carrillo, M., Pratt, V.M. & Hoffman, J.M. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics 19, 847 – 860 ( 2018 ).; Association for Molecular Pathology. Association for Molecular Pathology Position Statement: Best Practices for Clinical Pharmacogenomic Testing < https://www.amp.org/AMP/assets/File/positionTest‐statements/2019/Best_Practices_for_PGx_9_4_2019.pdf?pass=96 > ( 2019 ).; PharmGKB. The PharmGKB Blog < https://pharmgkb.blogspot.com/2020/05/pharmgkbTest‐response‐to‐fda‐table‐for.html > ( 2020 ).; American Society of Pharmacovigilance. STRIPE Collaborative Community < https://www.stopadr.org/stripeTest > ( 2021 ).; Knepper, T.C. & McLeod, H.L. When will clinical trials finally reflect diversity? Nature 557, 157 – 159 ( 2018 ).; Cavallari, L.H. et al. Multisite investigation of outcomes with implementation of CYP2C19 genotype‐guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc. Interv. 11, 181 – 191 ( 2018 ).; Deiman, B.A. et al. Reduced number of cardiovascular events and increased cost‐effectiveness by genotype‐guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth. Heart J. 24, 589 – 599 ( 2016 ).; Smith, D.M. et al. CYP2D6‐guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med. 21, 1842 – 1850 ( 2019 ).; Hulot, J.S. et al. Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI: results of the GIANT study. JACC Cardiovasc. Interv. 13, 621 – 630 ( 2020 ).; Brunette, C.A. et al. Pragmatic trials in genomic medicine: the integrating pharmacogenetics in clinical care (I‐PICC) study. Clin. Transl. Sci. 13, 381 – 390 ( 2020 ).; Oslin, D.W. et al. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial. Contemp. Clin. Trials 101, 106247 ( 2021 ).; Ensom, M.H., Davis, G.A., Cropp, C.D. & Ensom, R.J. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin. Pharmacokinet. 34, 265 – 279 ( 1998 ).; McInnes, G.T. The value of therapeutic drug monitoring to the practising physician–an hypothesis in need of testing. Br. J. Clin. Pharmacol. 27, 281 – 284 ( 1989 ).; Spector, R., Park, G.D., Johnson, G.F. & Vesell, E.S. Therapeutic drug monitoring. Clin. Pharmacol. Ther. 43, 345 – 353 ( 1988 ).; Tonkin, A.L. & Bochner, F. Therapeutic drug monitoring and patient outcome. A review of the issues. Clin. Pharmacokinet. 27, 169 – 174 ( 1994 ).; Vožeh, S. Cost‐effectiveness of therapeutic drug monitoring. Clin. Pharmacokinet. 13, 131 – 140 ( 1987 ).; Watson, I.D. & Thomson, A.H. The value of therapeutic drug monitoring to the practising physician–an hypothesis needing sensible application. Br. J. Clin. Pharmacol. 28, 619 – 620 ( 1989 ).; Regan, M.M. et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine‐responsive breast cancer: the breast international group 1–98 trial. J. Natl. Cancer Inst. 104, 441 – 451 ( 2012 ).; Rae, J.M. et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen‐treated breast cancer patients. J. Natl. Cancer Inst. 104, 452 – 460 ( 2012 ).; Goetz, M.P., Ratain, M. & Ingle, J.N. Providing balance in ASCO clinical practice guidelines: CYP2D6 genotyping and tamoxifen efficacy. J. Clin. Oncol. 34, 3944 – 3945 ( 2016 ).; Johnson, J.A., Hamadeh, I.S. & Langaee, T.Y. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies. J. Natl. Cancer Inst. 107, dju437 ( 2015 ).; Sanchez‐Spitman, A. et al. Tamoxifen pharmacogenetics and metabolism: Results from the prospective CYPTAM study. J. Clin. Oncol. 37, 636 – 646 ( 2019 ).; Goetz, M.P., Suman, V.J., Nakamura, Y., Kiyotani, K., Jordan, V.C. & Ingle, J.N. Tamoxifen metabolism and breast cancer recurrence: a question unanswered by CYPTAM. J. Clin. Oncol. 37, 1982 – 1983 ( 2019 ).; Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429 – 1436 ( 2009 ).; Mulder, T.A.M., de With, M., Del Re, M., Danesi, R. & Mathijssen, R.H.J. & van Schaik, R.H.N. Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER‐positive breast cancer patients: current status of a controversy. Cancers (Basel) 13, 771 ( 2021 ).; DeCensi, A. et al. Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low‐dose trial. NPJ Breast Cancer 7, 34 ( 2021 ).; Levine, G.N. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124, e574 – e651 ( 2011 ).; Claassens, D.M.F. et al. A genotype‐guided strategy for oral P2Y12 inhibitors in primary PCI. N. Engl. J. Med. 381, 1621 – 1631 ( 2019 ).; Pereira, N.L. et al. Effect of genotype‐guided Oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR‐PCI randomized clinical trial. JAMA 324, 761 – 771 ( 2020 ).; Pereira, N.L. et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y 12 inhibitor therapy: a meta‐analysis. JACC Cardiovasc. Interv. 14, 739 – 750 ( 2021 ).; National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia < https://www.nccn.org/professionals/physician_gls/pdf/all.pdfTest > ( 2021 ).; Relling, M.V. et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update. Clin. Pharmacol. Ther. 105, 1095 – 1105 ( 2019 ).; Newman, W.G. et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 12, 815 – 826 ( 2011 ).; Lichtenstein, G.R., Loftus, E.V., Isaacs, K.L., Regueiro, M.D., Gerson, L.B. & Sands, B.E. ACG clinical guideline: management of Crohn’s disease in adults. Am. J. Gastroenterol. 113, 481 – 517 ( 2018 ).; Shen, W.K. et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 136, e60 – e122 ( 2017 ).; Luzum, J.A. & Cheung, J.C. Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. Pharmacogenomics 19, 1203 – 1216 ( 2018 ).; Shugg, T., Pasternak, A.L., London, B. & Luzum, J.A. Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sources. NPJ Genom. Med. 5, 48 ( 2020 ).; Rasmussen‐Torvik, L.J. et al. Design and anticipated outcomes of the eMERGE‐PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin. Pharmacol. Ther. 96, 482 – 489 ( 2014 ).; Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N. & Conde, J.G. Research electronic data capture (REDCap)–a metadata‐driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377 – 381 ( 2009 ).; Ballinger, T.J. et al. Discerning the clinical relevance of biomarkers in early stage breast cancer. Breast Cancer Res. Treat. 164, 89 – 97 ( 2017 ).; Arwood, M.J. et al. Design and early implementation successes and challenges of a pharmacogenetics consult clinic. J. Clin. Med. 9, 2274 ( 2020 ).; Lee, Y.M., Manzoor, B.S., Cavallari, L.H. & Nutescu, E.A. Facilitators and barriers to the adoption of pharmacogenetic testing in an inner‐city population. Pharmacotherapy 38, 205 – 216 ( 2018 ).

الإتاحة: https://doi.org/10.1002/cpt.2327Test
https://hdl.handle.net/2027.42/169310Test

المؤلفون: Moeller, Sina, Canetta, Pietro A., Taylor, Annette K., Arguelles-Grande, Carolina, Snyder, Holly, Green, Peter H. R., Kiryluk, Krzysztof, Alaedini, Armin

مصطلحات موضوعية: Kidneys--Diseases, Gluten, Celiac disease, Immune response, IgA glomerulonephritis, Medicine

العلاقة: https://doi.org/10.7916/D8J38SVSTest

الإتاحة: https://doi.org/10.7916/D8J38SVSTest

المؤلفون: Rajavashisth, Tripathi B., Taylor, Annette K., Andalibi, Ali, Svenson, Karen L., Lusis, Aldons J.

المصدر: Science, 1989 Aug 01. 245(4918), 640-643.

الوصول الحر: https://www.jstor.org/stable/1704467Test

المؤلفون: Lau, Nga M., Green, Peter H. R., Taylor, Annette K., Hellberg, Dan, Ajamian, Mary, Tan, Caroline Z., Kosofsky, Barry E., Higgins, Joseph J., Rajadhyaksha, Anjali M., Alaedini, Armin

مصطلحات موضوعية: Medical and Health Sciences, Medicin och hälsovetenskap

وصف الملف: application/pdf

العلاقة: PLOS ONE, 2013, 8:6, s. e66155-; http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-205016Test; ISI:000320576400059

الإتاحة: https://doi.org/10.1371/journal.pone.0066155Test
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-205016Test

المؤلفون: Godler, David Eugeny, Tassone, Flora, Loesch, Danuta Zuzanna, Taylor, Annette K., Gehling, Freya, Hagerman, Randi Jenssen, Burgess, Trent, Ganesamoorthy, Devika, Hennerich, Debbie, Gordon, Lavinia, Evans, Andrew, Choo, K.H. Andy, Slater, Howard

مصطلحات موضوعية: Article

وصف الملف: text/html

العلاقة: http://hmg.oxfordjournals.org/cgi/content/short/ddq037v1Test; http://dx.doi.org/10.1093/hmg/ddq037Test

الإتاحة: https://doi.org/10.1093/hmg/ddq037Test
http://hmg.oxfordjournals.org/cgi/content/short/ddq037v1Test

المؤلفون: Sebastian, Siby, Spitzer, Silvia G, Grosso, Leonard E, Amos, Jean, Schaefer, Frederick V, Lyon, Elaine, Wolff, Daynna J, Hajianpour, Atieh, Taylor, Annette K, Millson, Alison, Stenzel, Timothy T

المصدر: Clinical Chemistry ; volume 50, issue 1, page 251-254 ; ISSN 0009-9147 1530-8561

مصطلحات موضوعية: Biochemistry (medical), Clinical Biochemistry

الإتاحة: https://doi.org/10.1373/clinchem.2003.028068Test
http://academic.oup.com/clinchem/article-pdf/50/1/251/32738345/clinchem0251.pdfTest